Comment on “Exploring PD-1 methylation in oral cancer: A crucial frontier in immunotherapy”

Comment on “Exploring PD-1 methylation in oral cancer: A crucial frontier in immunotherapy”

Saved in:

Bibliographic Details
Main Author:	Muthupandian Saravanan
Format:	Article
Language:	English
Published:	Elsevier 2024-09-01
Series:	Oral Oncology Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772906024004047
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Exploring PD-1 methylation in oral cancer: A crucial frontier in immunotherapy
by: Prasad Monisha, et al.
Published: (2024-03-01)

Letter to the editor: Comment on “the predictive role of PD-L1 in head and neck cancer: A systematic review and meta-analysis”
by: Muthupandian Saravanan
Published: (2024-09-01)

Comment on “PCNA and Ki67: Prognostic proliferation markers for oral cancer”
by: Muthupandian Saravanan
Published: (2024-06-01)

Comment on “Salivary exosomes as potential biomarkers in cancer”
by: Muthupandian Saravanan
Published: (2024-09-01)

Oral sex associated with the prevalence of human papillomavirus and oropharyngeal cancer: Is it the leading risk factor for head and neck cancers in the modern society?
by: Muthupandian Saravanan
Published: (2024-06-01)

Catalysts of change: Immunotherapy's frontier in oral oncology
by: Shyamaladevi Babu, et al.
Published: (2024-09-01)

Comment on “TGM3 - A novel biomarker as a potential diagnostic target for head and neck squamous cell carcinoma (HNSCC)”
by: Muthupandian Saravanan
Published: (2024-09-01)

Advancements in cancer research: 3D bioprinting as an optimal oral tumor model
by: Aruchamy Mohanprasanth, et al.
Published: (2024-03-01)

Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
by: Rangarirai Makuku, et al.
Published: (2021-01-01)

From PD-1/PD-L1 to tertiary lymphoid structures: Paving the way for precision immunotherapy in cholangiocarcinoma treatment
by: Fang-Ju Huang, et al.
Published: (2025-12-01)

Renal Tubular Acidosis an Adverse Effect of PD-1 Inhibitor Immunotherapy
by: Sandy El Bitar, et al.
Published: (2018-01-01)

Depth-dependent PD-L1 sampling of head and neck squamous cell carcinoma (HNSCC) – implications for PD-1/PD-L1 checkpoint inhibitor immunotherapy
by: Madhusudan Roy, et al.
Published: (2024-03-01)

Intrinsic PD‐L1 Degradation Induced by a Novel Self‐Assembling Hexapeptide for Enhanced Cancer Immunotherapy
by: Hongxia Zhang, et al.
Published: (2025-01-01)

Noninvasive Immunotyping and Immunotherapy Monitoring of Lung Cancers via Nuclear Imaging of LAG‐3 and PD‐L1
by: Lishu Zhao, et al.
Published: (2025-01-01)

Bispecific T-cell engagers in oral cancer immunotherapy
by: Veeraraghavan Vishnu Priya
Published: (2024-06-01)

Enhancing immunotherapy through PD‐L1 upregulation: the promising combination of anti‐PD‐L1 plus mTOR inhibitors
by: Anna Hernández‐Prat, et al.
Published: (2025-01-01)

Editorial: Beyond PD-1: novel checkpoint receptors and ligands as targets for immunotherapy
by: Jesse Haramati, et al.
Published: (2025-02-01)

Letter to the editor, “Depth-dependent PD-L1 sampling of head and neck squamous cell carcinoma (HNSCC) – Implications for PD-1/PD-L1 checkpoint inhibitor immunotherapy.”
by: Geetha Shanmugam
Published: (2024-09-01)

Neoadjuvant anti-PD-1-based immunotherapy: evolving a new standard of care
by: Drew M Pardoll, et al.
Published: (2025-01-01)

A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy
by: Jin Bian, et al.
Published: (2022-01-01)

Ginseng polysaccharides circumvent acquired resistance to anti-PD-1 immunotherapy in patients with non-small cell lung cancer
by: Jumin Huang, et al.
Published: (2025-02-01)

Exploring FBXO43 as a potential therapeutic target: Implications for oral cancer progression
by: Dhanraj Ganapathy, et al.
Published: (2024-06-01)

Advancements in immunotherapy: Transforming the landscape of oral cancer treatment
by: Madhan Krishnan, et al.
Published: (2024-09-01)

Targeting autophagy to enhance chemotherapy and immunotherapy in oral cancer
by: Xiaoli Zeng, et al.
Published: (2025-01-01)

Evaluating the influence of anti-PD-1 immunotherapy combined with IMRT on thyroid dysfunction in nasopharyngeal carcinoma
by: Liqianqi Chen, et al.
Published: (2025-01-01)

Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
by: Samit Chatterjee PhD, et al.
Published: (2017-07-01)

A retrospective multicenter study on the efficacy and safety of disitamab vedotin monotherapy versus combination with anti-PD-1 immunotherapy in advanced gastric cancer
by: Shuailei Dong, et al.
Published: (2025-01-01)

Immunotherapy in oral cancer treatment: Harnessing the immune system to combat oral squamous cell carcinoma
by: Santosh R. Patil
Published: (2024-06-01)

Bibliometric analysis of the research landscape of PD-1/PD-L1 inhibitors in the treatment of bowel cancer
by: Qingwei Luo, et al.
Published: (2025-02-01)

Liquid biopsy in oral cancer detection: A promising frontier in non-invasive diagnostics
by: Santosh R. Patil, et al.
Published: (2024-06-01)

Safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer: a study protocol for a phase 1 multicenter, open-label, single-arm clinical trial
by: Junya Furukawa, et al.
Published: (2025-02-01)

Exploring novel immunotherapy biomarker candidates induced by cancer deformation.
by: Se Min Kim, et al.
Published: (2024-01-01)

Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation
by: Oana Hangiu, et al.
Published: (2025-01-01)

Escherichia coli combination with PD-1 blockade synergistically enhances immunotherapy in glioblastoma multiforme by regulating the immune cells
by: Guochen Li, et al.
Published: (2025-02-01)

Comparison of the Efficacy and Safety of PD‐1/PD‐L1 Inhibitors in the Treatment of Small Cell Lung Cancer
by: Qichen Zhang, et al.
Published: (2025-01-01)

Exploring diagnostic frontiers in oral squamous cell carcinoma: A comprehensive review from immunohistochemistry to genomic profiling
by: Hema Suryawanshi, et al.
Published: (2024-09-01)

Repurposing Amlexanox to treat head and neck cancers: Increasing neoantigen expression to facilitate immunotherapy
by: Saravanan Sekaran, et al.
Published: (2024-06-01)

Analysis of tumor-infiltrating exhausted T cells highlights IL-6 and PD1 blockade as a combined immunotherapy strategy for non-small cell lung cancer
by: Lulu Zhang, et al.
Published: (2025-02-01)

Hotspots evolution and frontiers of immunotherapy for the treatment of acute myeloid leukemia: A bibliometric analysis
by: Nana Zhe, et al.
Published: (2025-12-01)

Prognostic significance of PD‐L2 expression in patients with oral squamous cell carcinoma—A comparison to the PD‐L1 expression profile
by: Manuel Weber, et al.
Published: (2019-03-01)